- FORCE Recommended Reads
- Update: PARP Inhibitor Research
- Brocade Study
- Personalizing Risk Assessment for BRCA1 and BRCA2 Mutation Carriers (Conference 2012 Recap)
- Genetic Testing in the Jewish Community—Are We Doing Enough? (Conference 2012 Recap)
- Breast Cancer Surveillance and Chemoprevention (Conference 2012 Recap)
- High-risk Breast Surveillance Resource Gaps
- Joining FORCEs Conference 2014
- Voices of FORCE and sidebar Conversations on the Impact of Hereditary Cancer in Our Lives
- Our New Collaboration with Basser Research Center
- Basser Research Projects
- What's New @ FORCE
Men and women aged 18 years or older who have advanced (metastatic) breast cancer due to a BRCA1 or BRCA2 gene mutation may qualify for the Brocade Study. The purpose of this medical research study is to determine the safety and effectiveness of the investigational PARP inhibitor, Veliparib in combination with chemotherapy in patients with advanced hereditary breast cancer. Each individual will be evaluated to determine his or her eligibility. Those who qualify will receive investigational medication or placebo, study-related medical exams, and lab tests at no charge. Compensation for time and travel may also be available. To see if you may qualify, call 1.855.5ONCOLOGY (1.855.566.2656) or visit BrocadeStudy.com.
Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.
This site has been made possible by a generous grant from Morphotek.